Stool DNA Screening for Colorectal Cancer. David Ahlquist, MD Carrol M Gatton Professor of Digestive Science Mayo Clinic, Rochester MN
|
|
- Delilah Weaver
- 5 years ago
- Views:
Transcription
1 Stool DNA Screening for Colorectal Cancer David Ahlquist, MD Carrol M Gatton Professor of Digestive Science Mayo Clinic, Rochester MN
2 Disclosures Relationship with Exact Sciences Mayo Clinic Equity investor Licensed technologies Dr. Ahlquist Scientific Advisor Inventor of licensed technology Research collaborator 2
3 Stool DNA Testing A more thoughtful approach and anyone can do it!
4 Effective Detection Effective Detection = S x C x A S = sensitivity C = compliance A = access 4
5 CRC Screening Tool Ideal Features Accurate detection Curable stage CRC Critical precursors (adenoma + serrated) Both R & L sides Noninvasive & safe Simple & convenient No prep or restrictions Affordable Widely distributable S C A 5
6 Stool DNA Testing High detection rates for CRC & precancer Unaffected by site Noninvasive No cathartic preparation No diet or med restriction Off-site collection Widely accessible Biologically rational Muco-cellular layer * * Ahlquist et al. Hum Pathol :51
7 Optimized Stool DNA Test Simple device for collection & mailing Buffered, stable >2 wks Targets multiple markers Methylated BMP3 & NDRG4 Mutant KRAS β-actin (human DNA) Hemoglobin (FIT) Sensitive multiplex DNA assay (QuARTS) Automated
8 Automated Stool Assay Developed by Exact Sciences Lidgard et al. CGH-Online 2013
9 Next Generation Stool DNA Testing for Detection of Colorectal Neoplasia: Early Clinical Evaluation Ahlquist, Zou, Domanico, Mahoney, Yab, Taylor, Thibodeau, Rabeneck, Kinzler, Vogelstein, Bjerregaard, Laurberg, Sørensen, Berger, Lidgard Multicenter casecontrol study N=678 CRC 253 Adv ad 130 Freezer archived specimens Stool DNA test Non-optimized prototype Covariate analyses 2012; 142:248 9
10 Cancer & Adenoma Detection Effect of Lesion Site Proximal Distal % Cancer Adenoma 1 cm 10
11 Sensitivity (%) Adenoma Detection Effect of Size P< ~ 1 >1 >2 >3 Adenoma Size (cm) 11
12 Detection of Sessile Serrated Polyps >1cm From Screen Setting: sdna vs FIT Heigh et al. GI Cancer Symposium (San Francisco 1/2013) 12
13 Factors NOT Affecting DNA Stool Markers Sex, Race, or Geography Smoking Alcohol NSAIDs Personal hx polyps FHx CRN Body mass Ahlquist et al. J Mol Biomark Diagn
14 Optimized & Automated Stool DNA Test Case-Control Study Lidgard et al. CGH-Online 2013 Prospective, blinded, multicenter Cases CRC 93 Adv precancer* 114 Controls Normal colonoscopy 641 * Advanced adenoma + serrated polyp >1cm
15 Cancer Detection Effect of Stage 95% 100% No stage effect p = NS 97% 96% 100% Overall sensitivity 98% 15
16 Adenoma Detection Effect of Size Sensitivity for HGD* 83% *94% found In lesions >2cm
17 Optimized Stool DNA Test Screen Setting Multicenter study completed (Imperiale et al) Cross-sectional, >10,000 Stools prior to screening colonoscopy Stool DNA vs FIT Topline data only Sensitivity CRC 92% Adv precancer* All 42% >2cm 66% (specificity 87%**) Currently under FDA & CMS review in USA * Adv adenoma + serrated polyp >1cm ** Normal includes polyps <1cm Superiority over FIT, all categories
18 Hypothetical Programmatic Sensitivity of Next Gen Stool DNA Testing Screen Frequency q 3 yr Cumulative Sensitivity, % Lesion Cohort Large Precancer* CRC Screen Screen (99) Screen * 1-2cm size cutoff, assume volume doubling time 6 yrs 18
19 Stool DNA Test Is More Accurate Than Plasma Septin 9 Test in Detecting Colorectal Neoplasia DA AHLQUIST, WR TAYLOR, DW MAHONEY, H ZOU, M DOMANICO, SN THIBODEAU, LA. BOARDMAN, BM BERGER, GP LIDGARD CGH 2012;10:272 Cancer Large Adenomas False Positives: sdna 7% pseptin9 27% 19
20 Plasma Septin9 in Screening Setting The PRESEPT Study Church et al. Gut Online 2/13/ asymptomatic persons, >50 yrs, prior to screening colonoscopy 91% specificity CRC (53) 48% Stage I 35% Stage II 63% 45% Stage III 46% Stage IV 77% Adv Ad (314) 11% HGD 12%
21 Conceptual Model Plasma Markers (vascular invasion) Distant metastasis? Stool Markers (exfoliation) Large Pre-cancer I II III IV Cancer 21
22 Stool Collection Not a barrier to compliance Much easier than bowel prep & completely noninvasive With pt-friendly collection device, return rate >95% Ann Intern Med 1988;108:607 Key determinants of screen test selection* Accuracy/effectiveness Convenience 3 rd party coverage *Mayo patient survey (unpublished) 22
23 Comparison of Tests FS Colo VC Cap sdna Accurate detection CRC + precursors - + +? + Both R & L sides - +/- +? + Operator-independent Noninvasive & safe Simple & convenient No prep or restricts Affordable???? + Widely distributable UGI Screen Capacity
24 Stool DNA Testing The Clear Winner!
Noninvasive Molecular Detection of Colorectal Neoplasia
Disclosures Noninvasive Molecular Detection of Colorectal Next Generation Approaches David Ahlquist August 7, 29 Relationship with Exact Sciences Mayo Clinic is equity investor Potential for future royalties
More informationColorectal Cancer Screening and Surveillance
1 Colorectal Cancer Screening and Surveillance Jeffrey Lee MD, MAS Assistant Clinical Professor of Medicine University of California, San Francisco jeff.lee@ucsf.edu Objectives Review the various colorectal
More informationReferences. Valorization
Valorization 179 Valorization 180 Valorization Colorectal cancer (CRC) is a major burden on the health care system with over 1,4millionnewlydiagnosedpatientsandalmost700,000deathsannually. 1 Becauseof
More informationIEHP UM Subcommittee Approved Authorization Guidelines Colorectal Cancer Screening with Cologuard TM for Medicare Beneficiaries
for Medicare Beneficiaries Policy: Based on our review of the available evidence, the IEHP UM Subcommittee adopts the use of Cologuard TM - a multi-target stool DNA test as a colorectal cancer screening
More informationAnalysis of Human DNA in Stool Samples as a Technique for Colorectal Cancer Screening. Summary
Page: 1 of 11 Last Review Status/Date: March 2015 Technique for Colorectal Cancer Screening Summary Detection of genetic abnormalities associated with colorectal cancer in stool samples has been proposed
More informationColorectal Cancer Screening: A Clinical Update
11:05 11:45am Colorectal Cancer Screening: A Clinical Update SPEAKER Kevin A. Ghassemi, MD Presenter Disclosure Information The following relationships exist related to this presentation: Kevin A. Ghassemi,
More informationA TEST FOR COLORECTAL CANCER THAT IS 92% SENSITIVE AND NON-INVASIVE. Stool DNA test
A TEST FOR COLORECTAL CANCER THAT IS 92% SENSITIVE AND NON-INVASIVE Stool DNA test THE NEW NON-INVASIVE SCREENING TEST FOR COLORECTAL CANCER Sensitive Clinically proven 1 Easy to use FDA approved COLOGUARD
More informationADVANCES IN FAECAL DNA TESTING FOR COLORECTAL CANCER SCREENING: A LITERATURE REVIEW FOR PRIMARY CARE PROVIDERS
ADVANCES IN FAECAL DNA TESTING FOR COLORECTAL CANCER SCREENING: A LITERATURE REVIEW FOR PRIMARY CARE PROVIDERS *Louise Babikow, Adelle Grant McAuley, Jenny Calhoun University of Pennsylvania, Philadelphia,
More informationUpdate on Exact Sciences Molecular CRC Screening Test. November 16 th, 2011
Update on Exact Sciences Molecular CRC Screening Test November 16 th, 2011 0 Safe Harbor Statement Certain matters contained in this presentation, other than historical information, consist of forward-looking
More informationDetection of Colorectal Serrated Polyps by Stool DNA Testing: Comparison with Fecal Immunochemical Testing for Occult Blood (FIT)
Detection of Colorectal Serrated Polyps by Stool DNA Testing: Comparison with Fecal Immunochemical Testing for Occult Blood (FIT) Russell I. Heigh 1 *, Tracy C. Yab 2, William R. Taylor 2, Fareeda T. N.
More informationFREQUENTLY ASKED QUESTIONS
FREQUENTLY ASKED QUESTIONS What is CRC? CRC (CRC) is cancer of the large intestine (colon), the lower part of the digestive system. Rectal cancer is cancer of the last several inches of the colon. Together,
More informationMedical Policy An independent licensee of the Blue Cross Blue Shield Association
Analysis of Human DNA in Stool Samples as a Page 1 of 11 Medical Policy An independent licensee of the Blue Cross Blue Shield Association Title: Analysis of Human DNA in Stool Samples as a Technique for
More informationCOLON CANCER SCREENING: AN UPDATE
Overview COLON CANCER SCREENING: AN UPDATE Siddharth Verma, DO, JD Rutgers New Jersey Medical School Background Screening Updates in Specific Populations African Americans CRC in the younger age USPSTF
More informationCologuard Screening for Colorectal Cancer
Pending Policies - Medicine Cologuard Screening for Colorectal Cancer Print Number: MED208.056 Effective Date: 08-15-2016 Coverage: I.Cologuard stool DNA testing may be considered medically necessary for
More informationMedical Policy An independent licensee of the Blue Cross Blue Shield Association
Analysis of Human DNA in Stool Samples as a Page 1 of 12 Medical Policy An independent licensee of the Blue Cross Blue Shield Association Title: Analysis of Human DNA in Stool Samples as a Technique for
More informationDiagnostics for the early detection and prevention of colorectal cancer.
Diagnostics for the early detection and prevention of colorectal cancer. Company Presentation May 2013 Safe Harbor Statement Certain statements made in this presentation contain forward-looking statements
More information11/9/2015 OUTLINE. Quality Indicators for the Doctor Performing Screening Colonoscopy: What you should expect from your Endoscopist
Quality Indicators for the Doctor Performing Screening Colonoscopy: What you should expect from your Endoscopist Anil K Sharma MD FACP Professor of Clinical Medicine, University of Rochester Chief of Gastroenterology,
More informationPharmacogenomic and Metabolite Markers for Patients Treated with Thiopurines
Pharmacogenomic and Metabolite Markers for Patients Treated with Thiopurines Applies to all products administered or underwritten by Blue Cross and Blue Shield of Louisiana and its subsidiary, HMO Louisiana,
More informationColorectal Cancer Screening: Cost-Effectiveness and Adverse events October, 2005
Colorectal Cancer Screening: Cost-Effectiveness and Adverse events October, 2005 David Lieberman MD Chief, Division of Gastroenterology Oregon Health and Science University Portland VAMC Portland, Oregon
More informationClinical Policy: DNA Analysis of Stool to Screen for Colorectal Cancer
Clinical Policy: to Screen for Colorectal Cancer Reference Number: CP.MP.125 Last Review Date: 07/18 See Important Reminder at the end of this policy for important regulatory and legal information. Coding
More informationABSTRACT. Background An accurate, noninvasive test could improve the effectiveness of colorectal-cancer screening.
The new england journal of medicine established in 1812 april 3, 2014 vol. 370 no. 14 Multitarget Stool DNA Testing for Colorectal-Cancer Screening Thomas F. Imperiale, M.D., David F. Ransohoff, M.D.,
More informationScreening for GI Cancer Past Present and Future. Prof. Bob Steele University of Dundee
Screening for GI Cancer Past Present and Future Prof. Bob Steele University of Dundee Worldwide Cancer Incidence Rates UK Cancer Incidence Rates Screening The detection of disease in asymptomatic subjects
More informationColorectal Cancer Screening. Paul Berg MD
Colorectal Cancer Screening Paul Berg MD What is clinical integration? AMA Definition The means to facilitate the coordination of patient care across conditions, providers, settings, and time in order
More informationPost-polypectomy follow-up after. removal of colorectal neoplasia
Post-polypectomy follow-up after removal of colorectal neoplasia Post-polypectomy endoscopic surveillance For each type of polyp BENEFIT 1. What is the risk of CRC/Adv. Neo. (AN) w/out surveillance?
More informationPage 1. Is the Risk This High? Dysplasia in the IBD Patient. Dysplasia in the Non IBD Patient. Increased Risk of CRC in Ulcerative Colitis
Screening for Colorectal Neoplasia in Inflammatory Bowel Disease Francis A. Farraye MD, MSc Clinical Director, Section of Gastroenterology Co-Director, Center for Digestive Disorders Boston Medical Center
More informationWEO CRC SC Meeting. Barcelona, Spain October 23, 2015
WEO CRC SC Meeting Barcelona, Spain October 23, 2015 Identification of serrated polyposis syndrome in the context of population-based CRC screening programs Evelien Dekker Academic Medical Center Amsterdam,
More informationCarol A. Burke, MD, FACG
Updated Guidelines for CRC C Screening and Surveillance Carol A. Burke MD, FACG, FASGE, FACP Cleveland Clinic, Cleveland, OH Gastroenterology t 2012;143:844 143 Gut 2010;59:666 1 Caveat for all Recommendations
More informationProspective Clinical Study of Circulating Tumor Cells For Colorectal Cancer Screening
Prospective Clinical Study of Circulating Tumor Cells For Colorectal Cancer Screening Results From a Multi-Year 620-Sample Study CRC: SLOW GROWING, PREVENTABLE POLYP TO CANCER CAN TAKE 5 TO 15 YEARS CANCER
More information[Type here] CG [Type here]
TRTs: - Physicians: 5:20 - Patients & Advocacy: 11:52 - Company: 4:32 Exact Sciences FDA Broll SUGGESTED B- ROLL & GRAPHICS Opening (white background, black lettering) SOUNDBITES FDA Approves Cologuard
More informationCorporate Presentation. August 2016
v Corporate Presentation August 2016 Safe harbor statement Certain statements made in this presentation contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933,
More informationColon Cancer Screening. Layth Al-Jashaami, MD GI Fellow, PGY 4
Colon Cancer Screening Layth Al-Jashaami, MD GI Fellow, PGY 4 -Colorectal cancer (CRC) is a common and lethal cancer. -It has the highest incidence among GI cancers in the US, estimated to be newly diagnosed
More informationPage 1. Cancer Screening for Women I have no conflicts of interest. Overview. Breast, Colon, and Lung Cancer. Jeffrey A.
Cancer Screening for Women 2017 Breast, Colon, and Lung Cancer Jeffrey A. Tice, MD Professor of Medicine Division of General Internal Medicine University of California, San Francisco I have no conflicts
More informationColorectal Cancer Screening in Ohio CHCs. Ohio Association of Community Health Centers
Colorectal Cancer Screening in Ohio CHCs Ohio Association of Community Health Centers 2 1/29/2015 Your Speakers Dr. Ted Wymyslo Ashley Ballard Randy Runyon 3 1/29/2015 Facts 3 rd most common cancer in
More informationColorectal Neoplasia. Dr. Smita Devani MBChB, MRCP. Consultant Physician and Gastroenterologist Aga Khan University Hospital, Nairobi
Colorectal Neoplasia Dr. Smita Devani MBChB, MRCP Consultant Physician and Gastroenterologist Aga Khan University Hospital, Nairobi Case History BT, 69yr male Caucasian History of rectal bleeding No change
More informationRx Only. Detecting Cancer In Blood.
Epi procolon is an FDA-approved blood test for colorectal cancer screening for patients who are unwilling or unable to be screened by recommended methods. Rx Only Intended Use, Contraindications, Warnings,
More informationUpdates in Colorectal Cancer Screening & Prevention
Updates in Colorectal Cancer Screening & Prevention Swati G. Patel, MD MS Assistant Professor of Medicine Division of Gastroenterology & Hepatology Gastrointestinal Cancer Risk and Prevention Clinic University
More informationBlood Based Screening
Plenary Session 4 CRC screening: The best modality is... Blood Based Screening Molnár, Béla M.D., PhD 2nd Dept. of Medicine Semmelweis Budapest Hungary There is no controversy: screening saves lives Irrefutable
More informationPolicy Specific Section: March 1, 2005 January 30, 2015
Medical Policy Fecal DNA Analysis for Colorectal Cancer Screening Type: Investigational / Experimental Policy Specific Section: Laboratory/Pathology Original Policy Date: Effective Date: March 1, 2005
More informationHow to Screen a patient with a Family History of Adenoma(s)
How to Screen a patient with a Family History of Adenoma(s) CDDW Banff 3-5-17 David Lieberman MD Chief, Division of Gastroenterology and Hepatology Oregon Health and Science University Disclosures 2016
More informationCRC Risk Factors. U.S. Adherence Rates Cancer Screening. Genetic Model of Colorectal Cancer. Epidemiology and Clinical Consequences of CRC
10:45 11:45 am Guide to Colorectal Cancer Screening SPEAKER Howard Manten M.D. Presenter Disclosure Information The following relationships exist related to this presentation: Howard Manten MD: No financial
More informationDiagnostics for the early detection and prevention of colon cancer
Diagnostics for the early detection and prevention of colon cancer Cologuard Test Crosswalk Proposal July 14 th, 2014 Colorectal cancer: the second-leading U.S. cancer killer Annual U.S. cancer mortality
More informationColon Screening in 2014 Offering Patients a Choice. Clark A Harrison MD The Nevada Colon Cancer Partnership
Colon Screening in 2014 Offering Patients a Choice Clark A Harrison MD The Nevada Colon Cancer Partnership Objectives 1. Understand the incidence and mortality rates for CRC in the US. 2. Understand risk
More informationImproving Outcomes in Colorectal Cancer: The Science of Screening. Colorectal Cancer (CRC)
Improving Outcomes in Colorectal Cancer: The Science of Screening Tennessee Primary Care Association October 23, 2014 Durado Brooks, MD, MPH Director, Prostate and Colorectal Cancers Colorectal Cancer
More informationAnalysis of Human DNA in Stool Samples as a Technique for Colorectal Cancer Screening
Analysis of Human DNA in Stool Samples as a Technique for Colorectal Cancer Screening Applies to all products administered or underwritten by Blue Cross and Blue Shield of Louisiana and its subsidiary,
More informationStool DNA methylation assays in colorectal cancer screening
Submit a Manuscript: http://www.wjgnet.com/esps/ Help Desk: http://www.wjgnet.com/esps/helpdesk.aspx DOI: 10.3748/wjg.v21.i35.10057 World J Gastroenterol 2015 September 21; 21(35): 10057-10061 ISSN 1007-9327
More informationA Blood-Based Biomarker for screening for Colorectal Cancer
WEO CRC SC Meeting Hong Kong, 25 Sep, 2017 A Blood-Based Biomarker for screening for Colorectal Cancer K.G. YEOH MBBS, MMed, FRCP (London), FRCP (Glasg), FAMS Dean, School of Medicine, National University
More informationProtocol. This trial protocol has been provided by the authors to give readers additional information about their work.
Protocol This trial protocol has been provided by the authors to give readers additional information about their work. Protocol for: Imperiale TF, Ransohoff DF, Itzkowitz SH, et al. Multitarget stool DNA
More informationPATIENT BROCHURE. 441 Charmany Dr 1 Madison WI, RX Only
PATIENT BROCHURE 441 Charmany Dr 1 Madison WI, 53719 844-870- 8870 Cologuard colorectal cancer screening test is a registered trademark of Exact Sciences Corporation. Indications for Use Cologuard is intended
More informationThe New Grade A: USPSTF Updated Colorectal Cancer Screening Guidelines, What does it all mean?
The New Grade A: USPSTF Updated Colorectal Cancer Screening Guidelines, What does it all mean? Robert A. Smith, PhD Cancer Control, Department of Prevention and Early Detection American Cancer Society
More informationBe it Resolved that FIT is the Best Way to Screen for Colorectal Cancer DEBATE
Be it Resolved that FIT is the Best Way to Screen for Colorectal Cancer DEBATE DEBATE Presenters PRESENTATION MODERATOR Dr. Praveen Bansal -MD, CCFP FCFP Regional Primary Care Lead, Integrated Cancer Screening,
More informationThe silence of the genes: clinical applications of (colorectal) cancer epigenetics
The silence of the genes: clinical applications of (colorectal) cancer epigenetics Manon van Engeland, PhD Dept. of Pathology GROW - School for Oncology & Developmental Biology Maastricht University Medical
More informationGeneral Session 7: Controversies in Screening and Surveillance in Colorectal Cancer
General Session 7: Controversies in Screening and Surveillance in Colorectal Cancer Complexities of Pathological Assessment: Serrated Polyps/Adenomas Carolyn Compton, MD, PhD Professor of Life Sciences,
More informationDouglas K. Rex, MD Indiana University Hospital Indianapolis, IN
Serrated Adenomas: What do they mean and what to do about them? Douglas K. Rex, MD Indiana University Hospital Indianapolis, IN Colorectal Cancer Molecular Basis Pathway Frequency Genes MSI Precursor Speed
More informationObjectives. Definitions. Colorectal Cancer Screening 5/8/2018. Payam Afshar, MS, MD Kaiser Permanente, San Diego. Colorectal cancer background
Colorectal Cancer Screening Payam Afshar, MS, MD Kaiser Permanente, San Diego Objectives Colorectal cancer background Colorectal cancer screening populations Colorectal cancer screening modalities Colonoscopy
More informationRazvan I. Arsenescu, MD Assistant Professor of Medicine Division of Digestive Diseases EARLY DETECTION OF COLORECTAL CANCER
Razvan I. Arsenescu, MD Assistant Professor of Medicine Division of Digestive Diseases EARLY DETECTION OF COLORECTAL CANCER Epidemiology of CRC Colorectal cancer (CRC) is a common and lethal disease Environmental
More informationGuidelines for Colonoscopy Surveillance After Screening and Polypectomy: A Consensus Update by the US Multi-Society Task Force on Colorectal Cancer
Guidelines for Colonoscopy Surveillance After Screening and Polypectomy: A Consensus Update by the US Multi-Society Task Force on Colorectal Cancer David A. Lieberman, 1 Douglas K. Rex, 2 Sidney J. Winawer,
More informationEARLY DETECTION OF COLORECTAL CANCER. Epidemiology of CRC
Razvan I. Arsenescu, MD Assistant Professor of Medicine Division of Digestive Diseases EARLY DETECTION OF COLORECTAL CANCER Epidemiology of CRC Colorectal cancer (CRC) is a common and lethal disease Environmental
More informationCT Colonography. A Radiologist s View of the Colon from Outside-In. Donny Baek, MD
CT Colonography A Radiologist s View of the Colon from Outside-In Donny Baek, MD Computed Tomography (CT) CT Image Reconstruction CT Image Reconstruction CT Image Reconstruction Colorectal Cancer Annual
More informationUK Bowel Cancer screening Dr Voi Shim Wong BsC MD FRCP. Consultant Gastroenterologist Accredited BCSP colonoscopist Whittington + UCL Hospitals
UK Bowel Cancer screening 2017 Dr Voi Shim Wong BsC MD FRCP Consultant Gastroenterologist Accredited BCSP colonoscopist Whittington + UCL Hospitals Bowel Cancer Contents UK Bowel Cancer Screening Programme
More informationColorectal Cancer Screening: Colonoscopy, Potential and Pitfalls. Disclosures: None. CRC: still a major public health problem
Colorectal Cancer Screening: Colonoscopy, Potential and Pitfalls Disclosures: None Jonathan P. Terdiman, M.D. Professor of Clinical Medicine University of California, San Francisco CRC: still a major public
More informationCTC vs. Colonoscopy for Surveillance After CRC? David Weinberg, MD, MSc June 1, 2018
CTC vs. Colonoscopy for Surveillance After CRC? David Weinberg, MD, MSc June 1, 2018 Goals of Post-operative CRC surveillance: Prevention or early detection of metachronous disease 30%-50% will suffer
More informationHamideh Salimzadeh, PhD Assistant Professor, Digestive Diseases Research Center,Tehran University of Medical Sciences, Shariati Hospital, North
Hamideh Salimzadeh, PhD Assistant Professor, Digestive Diseases Research Center,Tehran University of Medical Sciences, Shariati Hospital, North Kargar Avenue 14666 Tehran, Iran. Tel: +98-21-82415415 Fax:
More informationFECAL OCCULT BLOOD TEST (FOBT) Common Guaiac versus Immunochemical Test
FECAL OCCULT BLOOD TEST (FOBT) Common Guaiac versus Immunochemical Test LIMBACH-LABORATORY H E I D E L B E R G H J Roth H Schmidt-Gayk Estimated incidence of cancer in Europe and European Union, 2006 Limbach
More informationHow to start a screening Program? WEO Colorectal Cancer Screening Committee Meeting Brasilia Nov R. Sáenz, FACG,FASGE
How to start a screening Program? WEO Colorectal Cancer Screening Committee Meeting Brasilia Nov 11 2017 R. Sáenz, FACG,FASGE Wheel has been discovered already Policy Planning Thanks to GBD Big Data CRC
More information2. Describe pros/cons of screening interventions (including colonoscopy, CT colography, fecal tests)
Learning Objectives 1. Review principles of colon adenoma/cancer biology that permit successful prevention regimes 2. Describe pros/cons of screening interventions (including colonoscopy, CT colography,
More informationIn its October 5, 2015, draft recommendation (draft
USPSTF Colorectal Cancer Screening Guidelines: An Extended Look at Multi-Year Interval Testing Barry M. Berger, MD, FCAP; Marcus A. Parton, SB; and Bernard Levin, MD, FACP Managed Care & Healthcare Communications,
More informationChallenges for Colorectal Cancer Screening
Challenges for Colorectal Cancer Screening a Biomarker with No Standards! Prof. Emeritus Stephen P. Halloran University of Surrey W. Europe Top 20 Cancers Men Incidence & Mortality (2012) Women World -
More informationImproving you ADR. Robert Enns Colonoscopy Education Day October 2018
Improving you ADR Robert Enns Colonoscopy Education Day October 2018 ADR Applying to CSP Assume 50% ADR in FIT positive patients Out of 40 patients only 20 will have polyps Out of 20 likely 15 will be
More informationReferences Cleveland Clinic. Diseases and Conditions. Colorectal Cancer Overview. 29 October 2013
Colo-Alert Only available DNA based rapid test for early colorectal cancer detection. The earlier colon cancer is found, the easier it is to treat. This is why regular screening is worthwhile it has the
More informationChromoendoscopy or Narrow Band Imaging with Targeted biopsies Should be the Cancer Surveillance Endoscopy Procedure of Choice in Ulcerative Colitis
Chromoendoscopy or Narrow Band Imaging with Targeted biopsies Should be the Cancer Surveillance Endoscopy Procedure of Choice in Ulcerative Colitis Bret A. Lashner, M.D. Professor of Medicine Director,
More informationQuality of and compliance with colonoscopy in Lynch Syndrome surveillance: are we getting it right?
Quality of and compliance with colonoscopy in Lynch Syndrome surveillance: are we getting it right? Hartery K 1, Sukha A 1, Thomas-Gibson S 1, Thomas H 1,2, Latchford A 1,2. 1 Wolfson Endoscopy Unit, St.
More informationCorporate Presentation Fourth Quarter 2017
Corporate Presentation Fourth Quarter 2017 November 2017 1 Safe harbor statement This presentation contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as
More informationColorectal Cancer Prevention Quantity and Quality Count
Colorectal Cancer Prevention Quantity and Quality Count Ernesto Drelichman, MD Gastrointestinal Surgery & Endoscopy Providence Hospital Key Messages Colorectal cancer can be prevented Screening reduces
More informationEpi procolon 2.0 CE is a blood test for colorectal cancer screening.
Epi procolon 2.0 CE is a blood test for colorectal cancer screening. About Epi procolon 2.0 CE... 2 Screening Recommendations... 3 What You Should Know About Epi procolon 2.0 CE and the Septin 9 DNA Biomarker...
More informationBlood-based screening tests for colorectal cancer: Where are we and where are we going?
Blood-based screening tests for colorectal cancer: Where are we and where are we going? Timothy R. Church Division of Environmental Health Sciences University of Minnesota School of Public Health Background
More informationMissed Lesions at Endoscopy. Dr Russell Walmsley, MD, FRCP, FRACP Gastroenterologist WDHB Chair Endoscopy Guidance Group for New Zealand
Missed Lesions at Endoscopy Dr Russell Walmsley, MD, FRCP, FRACP Gastroenterologist WDHB Chair Endoscopy Guidance Group for New Zealand Missed Lesions at Endoscopy Is there a problem? With Gastroscopy
More informationAlberta Colorectal Cancer Screening Program (ACRCSP) Post Polypectomy Surveillance Guidelines
Alberta Colorectal Cancer Screening Program (ACRCSP) Post Polypectomy Surveillance Guidelines June 2013 ACRCSP Post Polypectomy Surveillance Guidelines - 2 TABLE OF CONTENTS Background... 3 Terms, Definitions
More informationColorectal Cancer Screening
Colorectal Cancer Screening An Integrated Care Pathway of the Collaborative Care Network Subject Matter Expert: Kevin Wolov, DO Pathway Custodian: Pat Czapp, MD First, a Friendly Reminder... This Integrated
More informationColorectal Cancer Screening and Surveillance
Medical Coverage Policy Effective Date...10/15/2017 Next Review Date...10/15/2018 Coverage Policy Number... 0148 Colorectal Cancer Screening and Surveillance Table of Contents Related Coverage Resources
More informationQuality Measures In Colonoscopy: Why Should I Care?
Quality Measures In Colonoscopy: Why Should I Care? David Greenwald, MD, FASGE Professor of Clinical Medicine Albert Einstein College of Medicine Montefiore Medical Center Bronx, New York ACG/ASGE Best
More informationFinding and Removing Difficult Polyps (safely)
Finding and Removing Difficult Polyps (safely) David Lieberman MD Chief, Division of Gastroenterology and Hepatology Oregon Health and Science University Colonoscopy Clouds Interval Cancers Interval Cancer:
More informationColorectal Cancer Screening: Recommendations for Physicians and Patients from the U.S. Multi-Society Task Force on Colorectal Cancer
1016 CLINICAL GUIDELINES CME Colorectal Cancer Screening: Recommendations for Physicians and Patients from the U.S. Multi-Society Task Force on Colorectal Cancer Douglas K. Rex, MD 1, C. R i chard B ol
More informationAchieving 80% by 2018: Working Together Can Get Us There. Zachary Gregg, MD Sentara Martha Jefferson April 18, 2016
Achieving 80% by 2018: Working Together Can Get Us There Zachary Gregg, MD Sentara Martha Jefferson April 18, 2016 1 Prostate 21% Lung & bronchus 14% Colon & rectum 8% Urinary bladder 7% Melanoma of skin
More informationPDF // POSITIVE COLON CANCER RESULTS
01 March, 2018 PDF // POSITIVE COLON CANCER RESULTS Document Filetype: PDF 268.79 KB 0 PDF // POSITIVE COLON CANCER RESULTS This cohort study evaluates the association between time to colonoscopy after
More informationFORTE: Five or Ten Year Colonoscopy for 1-2 Non-Advanced Adenomas
FORTE: Five or Ten Year Colonoscopy for 1-2 Non-Advanced Adenomas CRC Screening is Increasing Up to date with recommended screening in U.S.: 54% in 2002 65% in 2010 80% goal for 2018 More people are getting
More informationColorectal Cancer Screening. Daniel C. Chung, MD GI Unit and GI Cancer Genetics Service Massachusetts General Hospital
Colorectal Cancer Screening Daniel C. Chung, MD GI Unit and GI Cancer Genetics Service Massachusetts General Hospital March, 2018 CRC Epidemiology 4th most common malignancy in US (136,000 cases/yr) 2nd
More informationAnalysis of Human DNA in Stool Samples as a Technique for Colorectal Cancer Screening
Analysis of Human DNA in Stool Samples as a Technique for Colorectal Cancer Screening Applies to all products administered or underwritten by Blue Cross and Blue Shield of Louisiana and its subsidiary,
More informationColon Cancer Screening & Surveillance. Amit Patel, MD PGY-4 GI Fellow
Colon Cancer Screening & Surveillance Amit Patel, MD PGY-4 GI Fellow Epidemiology CRC incidence and mortality rates vary markedly around the world. Globally, CRC is the third most commonly diagnosed cancer
More informationDiagnostics for the early detection and prevention of colon cancer. Publication of DeeP-C Study Data in New England Journal of Medicine March 2014
Diagnostics for the early detection and prevention of colon cancer Publication of DeeP-C Study Data in New England Journal of Medicine March 2014 Safe Harbor Statement Certain statements made in this presentation
More informationProf Rupert Leong, Director of Endoscopy, Head of IBD Professor of Medicine UNSW, University of Sydney, Concord Hospital Australia IBDSydney
10:30-10:50 25 Sept 2017 Monday A-PSDE / WEO Colorectal Cancer Screening Committee (CRCSC) Meeting Room S228 (2/F) Prof Rupert Leong, Director of Endoscopy, Head of IBD Professor of Medicine UNSW, University
More informationColon Cancer Screening Past, Present & Future
Colon Cancer Screening Past, Present & Future Steve Lanspa, MD August 25, 2018 Dr. Lanspa has listed no financial interest/arrangement that would be considered a conflict of interest. Learning Objectives
More informationDebate: General surveillance/screening for colon cancer in a resource constrained environment is imperative
Debate: General surveillance/screening for colon cancer in a resource constrained environment is imperative Dr. Meryl Oyomno Department of surgery, University of Pretoria INTRODUCTION Screening is the
More informationColonoscopy Quality Data
Colonoscopy Quality Data www.dhsgi.com Introduction Colorectal cancer is the second leading cause of cancer related deaths in the United States, in men and women combined. In 2016, there are expected to
More informationScreening & Surveillance Guidelines
Chapter 2 Screening & Surveillance Guidelines I. Eligibility Coloradans ages 50 and older (average risk) or under 50 at elevated risk for colon cancer (personal or family history) that meet the following
More informationEarly detection and screening for colorectal neoplasia
Early detection and screening for colorectal neoplasia Robert S. Bresalier Department of Gastroenterology, Hepatology and Nutrition. The University of Texas. MD Anderson Cancer Center. Houston, Texas U.S.A.
More informationColon Polyps: Detection, Inspection and Characteristics
Colon Polyps: Detection, Inspection and Characteristics Stephen Kim, M.D. Assistant Professor of Medicine Interventional Endoscopy Services UCLA Division of Digestive Diseases September 29, 2018 1 Disclosures
More informationColorectal Cancer Screening
Recommendations from the U.S. Multi-Society Task Force on Colorectal Cancer Colorectal Cancer Screening Rex DK, Boland CR, Dominitz JA, Giardiello FM, Johnson DA, Kaltenbach T, Levin TR, Lieberman D, Robertson
More informationFinancial Disclosers
Slide 1 Colorectal Cancer Screening Jason Hemming, MD NESGNA November 15, 2014 Slide 2 Bio Slide 3 Financial Disclosers I have no actual or potential conflict of interest relation to this presentation
More information(Bowel) Cancer Screening an update. Mike Hulme-Moir Colorectal Surgeon CD NZ Bowel Screening Pilot
(Bowel) Cancer Screening an update Mike Hulme-Moir Colorectal Surgeon CD NZ Bowel Screening Pilot Screening The application of tests, examinations or other procedures. to sort out apparently well persons
More information